JNCE - Jounce Therapeutics, Inc.
| Previous Close | 7.83 |
| Open | 7.82 |
| Bid | 7.25 x 800 |
| Ask | 8.15 x 800 |
| Day's Range | 7.56 - 7.87 |
| 52 Week Range | 6.84 - 29.25 |
| Volume | 149,799 |
| Avg. Volume | 808,685 |
| Market Cap | 254.345M |
| Beta | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.93 |
| Earnings Date | Aug 7, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.50 |
- ACCESSWIRE•6 days ago
Free Technical Research on Intrexon and Three More Biotech Equities
LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on XON sign up now at www.wallstequities.com/registration. On Tuesday, July 10, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Tuesday's trading session in bullish territories.
- GlobeNewswire•last month
Investor Expectations to Drive Momentum within Core-Mark Holding, SSR Mining, iRhythm Technologies, Magic Software Enterprises, Jounce Therapeutics, and Akebia Therapeutics — Discovering Underlying Factors of Influence
NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Core-Mark ...
- InvestorPlace•last month
Agios Pharmaceuticals, Inc.Stock Is an Analyst Darling for Good Reason
As Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) closes at new highs, analysts are gushing over the company’s prospects. What is it about Agios stock that has the experts bullish on the company? Markets speculated that Celgene Corporation (NASDAQ:CELG) would buy Agios or Jounce Therapeutics, Inc. (NASDAQ:JNCE) back in April.
- ACCESSWIRE•last month
Today's Research Reports on Stocks to Watch: Deciphera Pharmaceuticals and Jounce Therapeutics
NEW YORK, NY / ACCESSWIRE / June 5, 2018 / While shares of Deciphera skyrocketed yesterday and hit a new high on positive data results, shares of Jounce Therapeutics saw the opposite result on its own ...
- Motley Fool•last month
Here's Why Jounce Therapeutics Fell Over 38% Today
The early-stage company's lead drug candidate disappointed in a phase 1/2 study.
- GlobeNewswire•last month
Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients with Advanced Cancers
Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today presented preliminary data from its ongoing Phase 1/2 ICONIC trial, an adaptive design, open-label trial evaluating JTX-2011 alone and in combination with nivolumab in patients with advanced solid tumors. Safety and preliminary clinical activity data from all evaluable patients across multiple tumor types will be presented in an oral presentation today, Saturday, June 2, 2018 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. “We are encouraged by the early signal of clinical activity in heavily pre-treated patients, accompanied by an ICOS pharmacodynamic biomarker.
- SmarterAnalyst•2 months ago
Recent Sell-Off in Jounce therapeutics’ (JNCE) Stock Is Unwarranted
In the wake of recently revealed abstracts from the 2018 ASCO meeting, Jounce therapeutics (NASDAQ:JNCE) stock price recently took a significant haircut, but was the drop justified? The goal of the therapy is to tip the balance between these two subtypes of T-cells towards the effector cells by depleting T-regs through antibody activity (ADCC) and encouraging growth of T-effector cells which express ICOS.
- ACCESSWIRE•2 months ago
Today’s Research Reports on Stocks to Watch: Loxo Oncology and Jounce Therapeutics
NEW YORK, NY / ACCESSWIRE / May 18, 2018 / Both Loxo Oncology and Jounce Therapeutics shares went in different directions after traders absorbed abstract reveals from each company. Shares of Loxo soared ...
- Motley Fool•2 months ago
Jounce Therapeutics Gets Throttled, Loses 35% Today
The clinical-stage upstart reported disappointing news that sparked pessimism.
- Motley Fool•2 months ago
Why J.C. Penney, NetEase, and Jounce Therapeutics Slumped Today
Find out which of these stocks fell because of earnings concerns.
- Benzinga•2 months ago
Jounce Therapeutics Stock Slides On Disappointing Data, Wells Fargo Downgrades
Wells Fargo Securities analyst Jim Birchenough downgraded Jounce from Outperform to Market Perform and lowered the price target from $37 to $13. The overall response rate for JTX-2011 as a monotherapy in gastric cancer and triple negative breast cancer, and for the JTX-2011-Opdivo combo in gastric cancer and TNBC, is underwhelming, Birchenough said in a Thursday note.
- GlobeNewswire•2 months ago
Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical Oncology Annual Meeting
CAMBRIDGE, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that data from its ongoing Phase 1/2 ICONIC trial, an adaptive design, open label trial evaluating JTX-2011 monotherapy and in combination with nivolumab, will be the subject of an oral presentation at the upcoming 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 1-5, 2018. Jounce has met its target enrollment for the Phase 1/2 ICONIC trial in its combination cohorts across four solid tumor types: gastric cancer, triple negative breast cancer (TNBC), head and neck squamous cell cancer (HNSCC) and non-small cell lung cancer (NSCLC), with most patients completing at least one efficacy assessment.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of JNCE.O earnings conference call or presentation 9-May-18 12:00pm GMT
Q1 2018 Jounce Therapeutics Inc Earnings Call
- GlobeNewswire•2 months ago
Jounce Therapeutics Reports First Quarter 2018 Financial Results
-Preliminary efficacy data from Phase 1/ 2 ICONIC trial to be presented as an oral presentation at the 2018 ASCO Annual Meeting-. -Company to host conference call and webcast today at 8:00 AM ET-. CAMBRIDGE, ...
- GlobeNewswire•2 months ago
Jounce Therapeutics to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018
Jounce Therapeutics, Inc. (JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report first quarter 2018 financial results on Wednesday, May 9, 2018.
- GlobeNewswire•3 months ago
Jounce Therapeutics to Present at Deutsche Bank 43rd Annual Health Care Conference
CAMBRIDGE, Mass., May 01, 2018-- Jounce Therapeutics, Inc., a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, ...
- Motley Fool•3 months ago
Biotech Fire Sale: 2 Top Stocks to Buy Next Week
Shares of Jounce Therapeutics and Sangamo Therapeutics were both hit hard last week by the marketwide sell-off. This dip is likely to prove temporary in both cases, however.
- Motley Fool•4 months ago
Jounce Therapeutics Is on Track to Report Key Data Soon
Investors should find out if Jounce's lead drug candidate could be a winner.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of JNCE.O earnings conference call or presentation 8-Mar-18 1:00pm GMT
Q4 2017 Jounce Therapeutics Inc Earnings Call
